Journal of Kidney Cancer and VHL

Scope & Guideline

Catalyzing progress in VHL research and treatment.

Introduction

Immerse yourself in the scholarly insights of Journal of Kidney Cancer and VHL with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2203-5826
PublisherCODON PUBLICATIONS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ KIDNEY CANCER VHL / J. Kidney Cancer VHL
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressLEVEL 9, 167 EAGLE ST, BRISBANE, QLD 4000, AUSTRALIA

Aims and Scopes

The Journal of Kidney Cancer and VHL focuses on disseminating significant research and findings related to kidney cancers, particularly emphasizing the genetic and clinical aspects associated with renal cell carcinoma and von Hippel-Lindau (VHL) disease. The journal aims to bridge clinical practice and research, providing insights into diagnosis, treatment, and management strategies.
  1. Kidney Cancer Research:
    The journal primarily publishes studies and reviews that explore various aspects of kidney cancer, including epidemiology, pathology, and treatment outcomes.
  2. VHL Disease Insights:
    A specialized focus on von Hippel-Lindau disease, including its genetic implications, associated tumors, and clinical management.
  3. Surgical Techniques and Outcomes:
    Research on different surgical modalities for kidney cancer treatment, including partial and radical nephrectomy, emphasizing innovative techniques and their outcomes.
  4. Clinical Trials and Patient Management:
    The journal discusses findings from clinical trials, especially regarding the management of metastatic renal cell carcinoma and the efficacy of new therapeutic agents.
  5. Case Reports and Reviews:
    Publication of unique case reports and comprehensive reviews that enhance understanding of rare presentations of kidney cancers and their management.
  6. Emerging Therapeutic Strategies:
    Exploration of novel treatment approaches, including immunotherapy and targeted therapy, particularly for advanced and metastatic kidney cancers.
Recent trends in the Journal of Kidney Cancer and VHL indicate a growing interest in specific themes that reflect the evolving landscape of kidney cancer research and treatment. These emerging areas highlight the journal's responsiveness to new challenges and advancements in the field.
  1. Genomic and Transcriptomic Studies:
    An increasing number of publications focus on the genomic and transcriptomic characteristics of kidney cancers, reflecting a trend towards personalized medicine and targeted therapies.
  2. Metastatic Renal Cell Carcinoma Management:
    There is a heightened emphasis on the management of metastatic renal cell carcinoma, including active surveillance strategies, which is crucial given the complexity of treatment options in this patient population.
  3. Innovations in Surgical Techniques:
    Emerging trends include comparative studies of surgical techniques, particularly minimally invasive approaches, highlighting advancements in surgical oncology for kidney cancer.
  4. Palliative Care and Quality of Life:
    A growing number of studies are addressing the role of palliative care in kidney cancer management, focusing on the impact of treatment on patients’ quality of life and symptom management.
  5. Interdisciplinary Approaches:
    Research increasingly emphasizes interdisciplinary approaches that integrate surgical, medical, and supportive care perspectives, reflecting a holistic view of kidney cancer management.

Declining or Waning

While the journal has maintained a strong focus on various aspects of kidney cancer and VHL, certain themes appear to be declining in prominence over recent years, reflecting shifts in research priorities or advancements in treatment methodologies.
  1. Basic Science Research:
    There has been a noticeable decrease in publications focused on the fundamental biological and molecular mechanisms underlying kidney cancer, possibly due to a shift towards translational and clinical research.
  2. Radiological Imaging Studies:
    Fewer articles are being published that solely focus on imaging techniques for kidney cancer diagnosis, suggesting a shift towards more integrated approaches that combine clinical and molecular data.
  3. Historical Case Studies:
    The journal has seen a decline in the number of historical case studies or retrospective analyses, which may indicate a move towards more innovative and prospective research designs.

Similar Journals

European Urology Oncology

Elevating the standards of urological oncology research.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Clinical Lung Cancer

Leading the way in comprehensive lung cancer exploration.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Case Reports in Oncological Medicine

Advancing oncology through shared clinical insights.
Publisher: HINDAWI LTDISSN: 2090-6706Frequency: 1 issue/year

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Chinese Clinical Oncology

Bridging experimental and clinical oncology for a healthier future.
Publisher: AME PUBLISHING COMPANYISSN: 2304-3865Frequency: 4 issues/year

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

CEN Case Reports

Elevating scientific discourse with peer-reviewed findings.
Publisher: SPRINGER JAPAN KKISSN: 2192-4449Frequency: 2 issues/year

CEN Case Reports is an influential journal published by Springer Japan KK, dedicated to advancing the knowledge and understanding of case reports across various scientific disciplines. The journal, identified by ISSN 2192-4449, focuses on disseminating high-quality, peer-reviewed case studies that illuminate unique clinical phenomena and contribute to the broader medical and scientific communities. Since its inception in 2018, CEN Case Reports has strived to provide a platform for researchers, professionals, and students to share groundbreaking findings while fostering collaborations across the globe. Although the journal currently does not adopt an open access model, it remains committed to accessibility through institutional subscriptions and individual purchase options. With a growing repository of insightful case reports, this journal plays a crucial role in enriching the evidence-based approach to medical practice and research, ensuring its relevance in a rapidly evolving field.

Cancer Research and Treatment

Empowering discoveries, enhancing treatments.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Leukemia Research Reports

Pioneering open access to vital leukemia insights.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Nephrologie & Therapeutique

Fostering dialogue for a healthier future in nephrology.
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1769-7255Frequency: 7 issues/year

Nephrologie & Therapeutique is a distinguished peer-reviewed journal published by JOHN LIBBEY EUROTEXT LTD, dedicated to the field of nephrology. Since its inception in 2005, this journal has been pivotal in disseminating high-quality research in the areas of kidney disease, renal therapies, and nephrological advancements, and it continues to serve as an essential resource for professionals, researchers, and students alike. With an ISSN of 1769-7255 and an E-ISSN of 1872-9177, the journal is indexed in Scopus and is currently ranked in the third quartile (Q3) within the nephrology category, showing significant contributions to the discipline, despite its current ranking of 64 out of 81. Although Nephrologie & Therapeutique does not operate under an open access model, it nevertheless provides valuable insights and updates on the latest findings and practices in nephrology, making it an important platform for academic discourse in this field. The journal's commitment to advancing knowledge and fostering interdisciplinary dialogue underscores its role as a key player in shaping future research and clinical practices in nephrology.

Kidney Diseases

Unlocking knowledge on kidney disorders and treatments.
Publisher: KARGERISSN: 2296-9381Frequency: 6 issues/year

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

NEPHROLOGY

Pioneering insights into kidney health and groundbreaking treatments.
Publisher: WILEYISSN: 1320-5358Frequency: 12 issues/year

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.